Genzyme to supply less than half of EU demand for Thyrogen
This article was originally published in Scrip
Executive Summary
For the next several months, Genzyme will only be able to meet around 45% of the demand for its Thyrogen (thyrotropin alfa) in the EU, the company has warned the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP). The problem should be resolved by July when logistical issues connected with the transfer of manufacturing should be resolved.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.